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We present the potential role of aptamers in elucidating the function of hypothetical proteins, as well as the possibilities provided by
bioinformatics for establishing a benchmark for aptamer-protein prediction methods. With these future perspectives, the role of hypothetical
proteins as target molecules for diagnostics and therapies could prove to be very useful in development of medical technology. 
 
*Corresponding author:  
E-mail: prash@bioclues.org. 
[a] Bioclues.org, India and Denmark  
[b]  Bioinformatics.Org, 28 Pope Street, Hudson, MA 01749, 
USA 
[c] Department of Micro- and Nanotechnology,  Technical 
University of Denmark, Produktionstorvet 423, 2800 Kgs. 
Lyngby, Denmark 
Introduction 
Aptamers are single stranded DNA or RNA or small 
peptide molecules designed to bind target molecules with 
high affinity and selectivity.  Aptamers have been developed 
to specifically bind small organic molecules and cellular 
toxins, viruses, ligands to important proteins enabling 
biomarker discovery and early treatment of diseases, with 
the latter subjected to using developed cell lines with 
defined genetic elements.1 In the recent past, DNA/RNA 
aptamers have been widely employed as a novel tool for 
elucidation of protein and/or nucleic acid interactions,2,3 
detection applications, regulation of gene expression, as well 
as purification of target molecules for diagnostics and 
therapies.4-6 The global market for aptamers is expected to 
make a turnover in excess of $1200 million showing a vast 
growth of the market from the $10 million. An overall 
120 % Compound Annual Growth Rate (CAGR) suggests 
that aptamers are emerging and will play a major role in all 
biotechnological, pharmaceutical and diagnostic 
applications.7 
Discussion 
On the technical side, when a protein or other target of 
interest is presented to an aptamer library, any unbound 
aptamers are washed away and aptamers that survive 
multiple bind/wash cycles are enriched. While aptamers 
undergo in vitro selection process, production of antibodies 
requires biological systems. In comparison with aptamers, 
the limitations of antibodies include inadequate supply, high 
costs and heterogeneity. To produce antibodies, the 
induction of an immune response is necessary. This 
procedure may discriminate target proteins that have a 
similar structure in comparison with endogenous proteins. 
Moreover, toxic compounds used as antigens or epitopes in 
a bioconjugated construct may lead to severe systemic 
effects and be ultimately lethal to the host organism.  By 
isolating aptamers in vitro using chemical modification, they 
can be easily produced for any target molecule. Moreover, 
they are known to be stable at elevated temperatures and can 
be regenerated easily. Due to this, the structural features 
determined by the functional mers can be retained despite 
temporary denaturation during experimental procedures. 
Theoretically, as for antibodies, all proteins are targets for 
aptamers, making it difficult to predict which aptamers 
would be better than others. However, several researchers 
are working on generation of aptamers with high specificity 
for chosen target proteins.8  
While aptamers are inexpensive compared to antibodies, 
the fundamental science of aptamers needs to mature to 
identify conditions/applications where they would be most 
suitable. To find more specific aptamers for a target protein, 
machine learning methods can help increase the likelihood 
in determining whether or not an aptamer can recognize the 
protein with high specificity. A recent report suggests that 
an improved understanding of the interactions between 
nucleic acid aptamers and their targets – the molecular 
recognition properties help improving design of aptamers.9  
A pull-down assay uses a small-scale affinity tag to an 
antibody similar to immunoprecipitation. The affinity 
system consists of a glutathione S-transferase (GST)-, 
polyHis- or streptavidin bead which is then immobilized and 
can be cleaved only by thrombin. In the recent years, single-
molecule pull-down (SiMPull) assay was introduced, 
facilitating probing of single macromolecular complexes 
directly in cell or tissue extracts.10 In the case of proteins, 
whose existence, function and even interacting partner have 
been theoretically (hypothetically) predicted but never 
experimentally demonstrated, pull-down assays can have a 
significant role. The use of biological data along with Gene 
Ontology functional dependencies specific to organelles 
could be of immense interest for deducing functions of 
uncharacterized proteins. However, based on the 
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conventional usage of antibodies, such pull-down assays 
would be highly expensive, counteracting the feasibility of 
the required experimentation. Hence, such hypothetical 
proteins (HP) and their interacting partners remain 
uncharacterized due to lack of feasible screening methods.  
Although the methods to identify the functional contexts of 
activity of the interacting protein have been presented, the 
necessary experimental boundary to characterize them does 
not exist.11 Therefore, we envisage the use of aptamers for 
pull-down assays or label-free detection to ascertain 
function of some classes of proteins such as HPs. 
Application of aptamers in this research area would have 
immense potentials as only few analytical techniques are 
known to be capable of detecting minute changes with a 
sensitivity matching that of antibodies. Targeting whole 
proteins and selection of specific residual sequences as 
epitopes is needed for functional characterization of HPs, 
such as Twinkle helicase, also known as Progressive 
External Opthalmoplegia (PEO) in humans, encoded by the 
gene C10orf2 which is similar to the GP4 helicase structure 
and an interacting partner of the DNA mismatch repair 
protein, MLH1. 
The ability to predict aptamer binding sites for known 
proteins, aided by bioinformatics predictions, could allow 
researchers to develop new diagnostic markers and 
procedures beyond the traditional medical diagnostics, as 
well as design new vaccines. Development of such 
bioinformatics prediction tools could also provide the 
fundamental basis and standard applicable for elucidation of 
functions and interacting partners of hypothetical proteins, 
lessening the scale of needed experimentation. Existing 
experimental data could be utilized as input for 
computational methods, to establish a benchmark for 
aptamer-protein prediction methods. We anticipate that 
aptamers can make good candidates for use in diagnostics 
and therefore can be tailored to address the role of 
hypothetical proteins in therapeutics, drug discovery and 
clinical applications in the future.   
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